Monitor for patent issuance and any subsequent clinical or partnership announcements that could validate the drug-delivery platform. Without revenue or near-term catalysts, this filing alone is unlikely to move the stock.
Price Chart
Executive Summary
Polyrizon filed a new U.S. divisional patent application (No. 19/823,285) covering its proprietary mucoadhesive polymer technology for intranasal drug delivery. This is a routine IP portfolio expansion for a clinical-stage biotech with no revenue or near-term catalysts — the filing does not change the company's fundamental outlook.
Key Facts
- Filed U.S. divisional patent application No. 19/823,285 titled 'Mucoadhesive Polymers for Nasal Drug Delivery'
- Application covers mucoadhesive platform for local or systemic delivery of therapeutic agents through nasal mucosa
- Company is a clinical-stage biotech with no approved products or disclosed revenue
- No financial data, guidance, or material agreements disclosed in the filing
Financial Impact
No financial impact disclosed — patent filing is a routine IP maintenance step for a pre-revenue company.
Risk Factors
- Patent may not issue or may issue in a narrower form than sought
- Company remains pre-revenue with no guarantee of commercializing the platform
- No disclosed timeline for clinical development of drug-delivery applications
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-106814 |
| Document: ea0307687-6k_polyrizon.htm | 0001213900-26-106814 |
| Document: 0001213900-26-106814-index-headers.html | 0001213900-26-106814 |
| Document: 0001213900-26-106814-index.html | 0001213900-26-106814 |
| Document: 0001213900-26-106814.txt | 0001213900-26-106814 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $9.01 | awaiting T+1 | — | $8.73 (−3.14%) |
Oct 27, 2026 today | Press Release | $9.01 | awaiting T+1 | — | $8.73 (−3.14%) |
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.73 (−9.75%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.73 (+9.19%) |
Sep 22, 2026 5w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.73 (−18.14%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.73 (+19.94%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.73 (+22.36%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.73 (+22.36%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.73 (+22.36%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.73 (−15.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers